COMPARISON
Calcitonin vs Lanreotide
5 attributes held for at least one of the two. 5 differ. Each value carries the register it came from and the date that register was read.
Answer
Calcitonin is authorised or registered in 8 and Lanreotide in 9 of the 10 registers read. Calcitonin: highest phase Phase 4 (after approval). Lanreotide: highest phase Phase 4 (after approval). 0 registered trials include both.
States no view on which is preferable, safer or more effective. Not medical advice.
| Calcitonin | Lanreotide | |
|---|---|---|
| Registered trials differs | 154 clinicaltrials.gov · 2026-10-03 | 125 clinicaltrials.gov · 2026-10-03 |
| FDA label differs | FDA-approved: CALCITONIN SALMON openfda · 2026-10-03T17:23:44.062Z | FDA-approved: Lanreotide Acetate openfda · 2026-10-03T17:23:44.062Z |
| EU authorisation differs | Withdrawn ema · 2026-10-03 | Nothing on record ema read 2026-08-31 |
| EU withdrawn on differs | 2008-11-20 ema · 2026-10-03 | Not checked no record of "withdrawnOn" for lanreotide |
| ATC code differs | H05BA01 ema · 2026-10-03 | Not checked no record of "atcCode" for lanreotide |
SIDE EFFECTS
Most common side effects, each beside its own placebo
| Side effect | Calcitonin | placebo | Lanreotide | placebo |
|---|---|---|---|---|
| Arthralgia | 16.5% | 21.9% | 8.0% | 8.2% |
| Nausea | 14.8% | 3.0% | 11.0% | 12.0% |
| Back Pain | 10.0% | 10.6% | 8.0% | 10.3% |
| Diarrhoea | 8.7% | 5.3% | 19.5% | 23.6% |
| Hypertension | 6.0% | 7.7% | 8.8% | 5.6% |
| Hot flush | 16.9% | 4.3% | - | - |
| Dyspepsia | 9.2% | 4.1% | - | - |
| Influenza | 7.0% | 6.9% | - | - |
| Nasopharyngitis | 6.8% | 8.0% | - | - |
| Dizziness | 6.2% | 3.3% | - | - |
| Abdominal pain | - | - | 16.8% | 15.9% |
| Fatigue | - | - | 12.2% | 14.6% |
| Vomiting | - | - | 10.8% | 7.8% |
| Headache | - | - | 10.7% | 9.4% |
| Decreased appetite | - | - | 8.0% | 8.6% |
Trial register Calcitonin: 2 placebo-controlled trials; Lanreotide: 5. Each peptide is compared with placebo in its own trials, not with the other: a dash means the event is not in that peptide's top list. Calcitonin side effects · Lanreotide side effects
LEGAL STATUS
Approval in each country read
| Country | Calcitonin | Lanreotide | Register |
|---|---|---|---|
| United States | FDA-approved | FDA-approved | Regulator FDA |
| European Union | Withdrawn | Not on the register | Regulator EMA |
| United Kingdom | Authorised | Authorised | Regulator MHRA |
| Canada | Authorised | Authorised | Regulator Health Canada |
| Australia | Registered | Registered | Regulator TGA |
| Switzerland | Authorised | Authorised | Regulator Swissmedic |
| Brazil | Registado | Registado | Regulator ANVISA |
| Serbia | Not on the register | Authorised | Regulator ALIMS |
| Singapore | Registered | Registered | Regulator HSA |
| Turkey | Ruhsatli | Ruhsatli | Regulator TITCK |
Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.